MedPath

Cushing's Disease Complications

Completed
Conditions
Cushing's Disease
Interventions
Other: Exams and questionnaires
Registration Number
NCT02568982
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

This study aims at investigating the complications of Cushing's disease in "de novo" patients. A series of investigations will assay before treatment and every year thereafter during a 3 years follow-up period the various complications of the disease. These investigations will determine the presence and severity of cardiovascular, metabolic, and bone complications as well as the Quality of Life. Outcome of these complications after treatment, especially after pituitary surgery will be monitored, as well as cortisol levels.

Detailed Description

At inclusion the following will be investigated and recorded :

* demographic and personal medical history.

* Familial medical history related to osteoporosis, cardiovascular disorders and thromboembolism.

* Current medical treatment.

* Physical examination.

* Assessment of basal 24hrs urinary cortisol and salivary cortisol.

- At baseline (i.e. before specific treatment of Cortisol excess):

* physical examination,

* routine biology,

* HbA1C, fasting glucose and oral glucose load,

* cholesterol, triglyceride, HDL \& LDL,

* coagulation and fibrinolysis investigation,

* 24hrs urinary cortisol and salivary cortisol, urinary labstick test.

* EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US,

* ophthalmology examination,

* spine X-Ray, bone densitometry,

* QoL questionnaires (SF-36, QoLCushing, Beck BDI-II).

Every year during a 3 years follow-up the following will be investigated :

* Current medical treatment.

* Physical examination.

* Assessment of basal routine biology,

* HbA1C, fasting glucose,

* cholesterol, triglyceride, HDL \& LDL,

* coagulation and fibrinolysis investigation,

* 24hrs urinary cortisol and salivary cortisol, urinary labstick test.

* EKG, cardiac ultrasound, cardiac CT-scan (if abnormal initially), arterial and venous US,

* ophthalmology examination, bone densitometry,

* QoL questionnaires (SF-36, QoLCushing, Beck BDI-II).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Cushing's disease diagnosed by complementary explorations according to the National Program of Diagnosis and Care of the Cushing 's disease
Exclusion Criteria
  • other cause of Cushing's syndrome
  • known inherited syndrome having for consequence an hormonal hypersecretion (NEM-1, complexe of carney, McCuneAlbright syndrome)
  • patient does not understand french
  • life expectancy of less than 6 months
  • pregnant women
  • dependent patient

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
patient with Cushing's diseaseExams and questionnaires-
Primary Outcome Measures
NameTimeMethod
number of complications (hormonal and imaging results, quality of life) per patient (composite)from diagnosis until 3 years of treatment

Evaluate the frequency of :

* metabolic complications (HbA1C, fasting glucose and oral glucose load, cholesterol, triglyceride, HDL \& LDL, coagulation and fibrinolysis investigation, 24hrs urinary cortisol and salivary cortisol, urinary labstick test)

* cardiovascular thromboembolic complications (EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US)

* bone complications (spine X-Ray, bone densitometry)

* quality of life alteration measured by questionnaires (SF36, QoLCushing, Beck BDI-II)

Secondary Outcome Measures
NameTimeMethod
Remission rate of Cushing's disease1 year after treatment

Trial Locations

Locations (1)

AP-HP, Hôpital Cochin

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath